Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
Status:
Completed
Trial end date:
2018-06-28
Target enrollment:
Participant gender:
Summary
A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative
Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221
vs. placebo in patients with uncomplicated influenza or other ARVI during a 3-day treatment.
The primary objective of the study is to demonstrate the difference in time before the onset
of a sustained improvement in clinical symptoms according to the Modified Jackson Scale for
ARVI and to determine the optimal dose of XC221 in the treatment of influenza and other ARVI.